Related Experiment Video
Updated: Mar 31, 2026
10:21
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
10.6K
Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia
Heriberto Bruzzoni-Giovanelli1,2, Juan R González3,4,5, François Sigaux6
1Université Paris Diderot, Sorbonne Paris Cité UMRS 1160 INSERM, Paris, France.
Oncotarget
|October 17, 2015
Summary
Inherited genetic factors influence chronic myelogenous leukemia (CML) risk. Researchers identified specific gene variations and developed a genetic risk score, aiding in CML predisposition research and understanding disease development.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Inherited factors contributing to chronic myelogenous leukemia (CML) risk are largely unknown.
- Understanding genetic predisposition is crucial for CML prevention and treatment strategies.
Purpose of the Study:
- To identify inherited genetic variations associated with CML risk.
- To develop a predictive genetic risk score for CML predisposition.
Main Methods:
- Genome-wide analysis using a DNA chip with 16,561 single nucleotide polymorphisms (SNPs) in 1,916 candidate genes.
- Analysis of 437 CML patients and 1,144 healthy controls.
- Statistical association analyses (SNP, haplotype, classification tree) and creation of a CML-risk-allele score.
Main Results:
- 139 SNPs passed multiple comparisons, with genes like HDAC9, SLC15A1, and PSM family showing significant associations.
- Certain rare allele combinations increased CML risk two to threefold.
- A five-SNP genetic score accurately discriminated CML status (AUC: 0.61) and was linked to younger age at diagnosis and differential gene expression.
Conclusions:
- Haplotypes and a novel genetic risk score are significantly associated with CML predisposition.
- Identified SNPs provide targets for further research into the role of these genes in CML pathogenesis.
- This genetic score may aid in identifying individuals at higher risk for CML.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
112
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:27Principles of Pharmacogenetics: Types of Genetic Variants
97
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
97
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
123
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
123
02:26Comparing Copy Number Variations and SNPs
19.3K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
19.3K
01:27Pharmacogenetics of Drug Metabolism: Overview
117
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
117